- Considered intangible assets, patents offer a significant competitive advantage and value for companies
- Lexaria Bioscience views its growing patent portfolio as a solid foundation upon which to build future commercial partnerships
- The company recently announced the receipt of three new patents in the E.U., Canada, and the U.S.
- The issuance of the latest three patents grows Lexaria’s patent portfolio to 46 granted patents worldwide
Lexaria’s multi-patented DehydraTECH(TM) “drug delivery platform technology” offers proven increased bioavailability, enhancing the way active pharmaceutical ingredients (“APIs”) enter the bloodstream by promoting more effective oral delivery, helping with speed of onset, and brain absorption of APIs. Strong patents covering this important technology are a critical factor for Lexaria.
A robust patent portfolio has always been a metric that investors use to judge a biotechnology or biopharmaceutical company. “A strong patent position is not only an important goal for a successful biotechnology business but also the primary asset by which a company will be valued during all stages of its development. Therefore, a patent portfolio must be as well designed and solidly constructed from the outset as all other aspects of the business,” a 2001 article conveyed (https://cnw.fm/1mIaw).
Not much has changed since the article’s publication, with a recent Forbes write-up observing that intangible assets, which include trade secrets, proficiency and expertise, trademarks, copyrights, and patents, accounted for 90% of the S&P 500’s total assets in 2020. This is a substantial increase from 1975’s figures, when intangible assets only accounted for 17% of the total assets, while tangible assets comprised the balance. The article noted that the explosion of intangible assets shows “that there is value to companies’ intellectual property (“IP”),” with patents holding the potential to be “far more valuable than physical assets” because they can offer businesses a competitive advantage (https://cnw.fm/vd9Au).
For its part, Lexaria Bioscience (NASDAQ: LEXX), a global innovator of drug delivery platforms, looks at the value of its growing patent portfolio not only from a commercialization perspective but also from an IP protection standpoint. As CEO Chris Bunka put it in his 2024 letter to shareholders, “Those patents, when granted, can form the foundation upon which future commercial relationships are built” (https://cnw.fm/uBi8c).
The company recently received three new patents in the European Union (“E.U.”), Canada, and the United States (https://cnw.fm/WII23). In the EU, Lexaria received a newly granted patent in its patent family #6: Transdermal and/or Dermal Delivery of Lipophilic Active Agents. This patent is validated in Austria, the Czech Republic, France, the U.K., Germany, Italy, Poland, Spain, Sweden, and Switzerland. It is the company’s second patent in this family, following receipt of the first patent in Canada.
In Canada, Lexaria received a new patent granted in patent family #18: Compositions and Methods for Enhanced Delivery of Antiviral Agents. It is the company’s fourth granted patent in this patent family and follows the receipt of a patent-granted status in the U.S., Australia, and Japan. Across the border in the U.S., Lexaria received its fourth granted U.S. patent in the patent family #24: Compositions and Methods for Treating Epilepsy.
The latter two patents granted in Canada and the U.S. build on the company’s research development initiatives and safeguard discoveries thereof. In 2021, Lexaria conducted research under its antiviral drug program, evidencing its patented DehydraTECH(TM) technology increased the delivery of five compounds from three antiviral classes into the bloodstream. The studies found that the drug-delivery improvement rates ranged between 42% and 204% (https://cnw.fm/DYgMn).
In addition, Lexaria in 2022 completed an animal seizure study that demonstrated that DehydraTECH-processed cannabidiol (“CBD”) resulted in enhanced seizure-inhibiting performance compared to Epidiolex(R), one of the world’s leading anti-seizure drugs. According to the company, the study’s results demonstrated the ability of DehydraTECH-CBD to reduce or eliminate seizure activity in animals and to, in some instances, even surpass the performance of Epidiolex (https://cnw.fm/EZw0Y).
The issuance of the latest three patents grows Lexaria’s patent portfolio to 46 granted patents worldwide. The company nonetheless continues to expect additional patents to be awarded in the future, given that it retains many valid patent applications throughout the world.
For more information, visit the company’s website at www.LexariaBioscience.com.
NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX
About HempWire
HempWire (“HW”) is a specialized communications platform with a focus on hemp-related news, information, and the latest developments in the hemp sector. HempWire is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, HW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, HW brings its clients unparalleled recognition and brand awareness. HW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from HempWire, text “HempWire” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.HempWire.com
Please see full terms of use and disclaimers on the HempWire website applicable to all content provided by HW, wherever published or re-published: https://www.HempWire.com/Disclaimer
HempWire
Denver, Colorado
www.HempWire.com
303.498.7722 Office
Editor@HempWire.com
HempWire is powered by IBN